Cyclacel Pharmaceuticals Inc., of Berkeley Heights, N.J. reported that an independent data and safety monitoring board (DSMB) for the company's phase III study in acute myeloid leukemia (AML), called SEAMLESS, has completed its fourth planned safety review and recommended that the study should continue as planned without any modifications.